ABOUT EQIPD

Turnhoutseweg 30
2340 Beerse
Belgium

Project Leader

Dr. Thomas Steckler

Janssen Pharmaceutica NV

Phone number: +32 14 607 373 

Send message

Project Staff

Kaitlyn Hair

Phone number: +44 131 465 957 7 

Send message

Filipa Lopes

Phone number: +35 191 327 579 0 

Send message

Ezgi Tanriver

Phone number: +44 131 465 957 7 

Send message

Dr. med. Heidi De Smedt

Phone number: +32 14 607 061 

Send message

Dr. Pim Drinkenburg

Phone number: +32 14 602 631 

Send message

Dr. Anja Gilis

Phone number: +32 14 606 216 

Send message

Lieve Heylen

Phone number: +32 14 605 332 

Send message

Tom Lavrijssen

Phone number:  +32 14 603 783 

Send message

Dr. David Gallacher

Phone number: +32 14 603 009 

Send message

Dr. Juan Diego Pita Almenar

Phone number: +32 14 641 839 

Send message

Dr. Greet Teuns

Phone number: +32 14 603 079 

Send message

Dr. Tom Van de Casteele

Phone number: +32 14 641 343 

Send message

Henk Van Der Linde

Phone number: +32 14 606 196 

Send message

Dr. Luc Ver Donck

Phone number: 0032 14 60 28 37

Send message

Kathleen Wuyts

Janssen Pharmaceutica NV

Phone number: +32 14 607 843 

Send message

Institute presentation

Janssen Pharmaceutica NV (Janssen) is a subsidiary of the global pharmaceutical, medical devices and consumer packaged goods manufacturer, Johnson & Johnson. The main research facilities in Europe are located in Beerse, Belgium, with research focused around the therapeutic areas of Neuroscience, Oncology, and Infectious Diseases. Janssen strives to eliminate disease through developing transformational medical solutions and making these accessible to people around the world. To achieve this, Janssen directs its efforts and resources on diseases where the unmet medical need is high, its internal capabilities strong, and the external science it can partner with compelling. With over 50 years of experience in pharmaceutical R&D, Janssen enjoys an international reputation for pharmaceutical innovation and quality. In 2010 Janssen launched the Discovery Data Integrity initiative (DDI) across the global Drug Discovery environment, setting up a global Quality Management System and Maintenance Program in the non-regulated space, with initial focus on internal preclinical data quality and subsequent expansion to also include data generated by external collaborators and service providers generating data on behalf of the company. As part of these activities, Janssen improved its data management processes and implemented internal guidelines, training an awareness campaigns, as well as a spot check program. Over the last years, Janssen gained increasing experience in collaborations with external partners to improve preclinical data quality processes. Neuroscience is one of Janssen’s key areas with a long and successful drug development history and several CNS drugs on the market, such as haloperidol, risperidone and paliperidone, methylphenidate, fentanyl and galantamine, the latter for the symptomatic treatment of Alzheimer’s disease. In fact, Alzheimer’s disease remains a focus area within Janssen Neuroscience Drug Discovery. Naturally, Janssen also has the internal safety and toxicology capabilities needed in support of drug development.